

NASA/TM—2005-213824



By Different Cellular Mechanisms, Lymphatic Vessels Sprout by Endothelial Cell Recruitment Whereas Blood Vessels Grow by Vascular Expansion

Patricia A. Parsons-Wingerter
Glenn Research Center, Cleveland, Ohio

Terri L. McKay
National Center for Space Exploration Research, Cleveland, Ohio

Dmitry Leontiev
Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, Ohio

Terence K. Condrich
RS Informations Systems, Inc., Cleveland, Ohio

Paul E. DiCorleto
Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, Ohio

The NASA STI Program Office . . . in Profile

Since its founding, NASA has been dedicated to the advancement of aeronautics and space science. The NASA Scientific and Technical Information (STI) Program Office plays a key part in helping NASA maintain this important role.

The NASA STI Program Office is operated by Langley Research Center, the Lead Center for NASA's scientific and technical information. The NASA STI Program Office provides access to the NASA STI Database, the largest collection of aeronautical and space science STI in the world. The Program Office is also NASA's institutional mechanism for disseminating the results of its research and development activities. These results are published by NASA in the NASA STI Report Series, which includes the following report types:

- **TECHNICAL PUBLICATION.** Reports of completed research or a major significant phase of research that present the results of NASA programs and include extensive data or theoretical analysis. Includes compilations of significant scientific and technical data and information deemed to be of continuing reference value. NASA's counterpart of peer-reviewed formal professional papers but has less stringent limitations on manuscript length and extent of graphic presentations.
- **TECHNICAL MEMORANDUM.** Scientific and technical findings that are preliminary or of specialized interest, e.g., quick release reports, working papers, and bibliographies that contain minimal annotation. Does not contain extensive analysis.
- **CONTRACTOR REPORT.** Scientific and technical findings by NASA-sponsored contractors and grantees.

- **CONFERENCE PUBLICATION.** Collected papers from scientific and technical conferences, symposia, seminars, or other meetings sponsored or cosponsored by NASA.
- **SPECIAL PUBLICATION.** Scientific, technical, or historical information from NASA programs, projects, and missions, often concerned with subjects having substantial public interest.
- **TECHNICAL TRANSLATION.** English-language translations of foreign scientific and technical material pertinent to NASA's mission.

Specialized services that complement the STI Program Office's diverse offerings include creating custom thesauri, building customized databases, organizing and publishing research results . . . even providing videos.

For more information about the NASA STI Program Office, see the following:

- Access the NASA STI Program Home Page at <http://www.sti.nasa.gov>
- E-mail your question via the Internet to help@sti.nasa.gov
- Fax your question to the NASA Access Help Desk at 301-621-0134
- Telephone the NASA Access Help Desk at 301-621-0390
- Write to:
NASA Access Help Desk
NASA Center for AeroSpace Information
7121 Standard Drive
Hanover, MD 21076



By Different Cellular Mechanisms, Lymphatic Vessels Sprout by Endothelial Cell Recruitment Whereas Blood Vessels Grow by Vascular Expansion

Patricia A. Parsons-Wingerter
Glenn Research Center, Cleveland, Ohio

Terri L. McKay
National Center for Space Exploration Research, Cleveland, Ohio

Dmitry Leontiev
Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, Ohio

Terence K. Condrich
RS Informations Systems, Inc., Cleveland, Ohio

Paul E. DiCorleto
Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, Ohio

National Aeronautics and
Space Administration

Glenn Research Center

Acknowledgments

The authors thank Judy Drazba, Cleveland Clinic Foundation, for helpful consultation on fluorescence imaging and histology. We thank Gavin Thurston, Regeneron, Inc.; Krishnan Radhakrishnan and Robert Hendricks, NASA Glenn Research Center; and Bela Anand-Apte, Cleveland Clinic Foundation, for critical reading of the manuscript and discussion of results. The research was supported by Internal Research and Development Award (IRD04-54), BioScience and Engineering/ Fluid Physics; NASA Glenn Research Center.

Trade names or manufacturers' names are used in this report for identification only. This usage does not constitute an official endorsement, either expressed or implied, by the National Aeronautics and Space Administration.

Available from

NASA Center for Aerospace Information
7121 Standard Drive
Hanover, MD 21076

National Technical Information Service
5285 Port Royal Road
Springfield, VA 22100

Available electronically at <http://gltrs.grc.nasa.gov>

By Different Cellular Mechanisms, Lymphatic Vessels Sprout by Endothelial Cell Recruitment Whereas Blood Vessels Grow by Vascular Expansion

Patricia Parsons-Wingarter
National Aeronautics and Space Administration
Glenn Research Center
Cleveland, Ohio 44135

Terri L. McKay
National Center for Space Exploration Research
Cleveland, Ohio 44135

Dmitry Leontiev
Cleveland Clinic Foundation
Lerner Research Institute
Cleveland, Ohio 44195

Terence K. Condrich
RS Information Systems
Cleveland, Ohio 44135

Paul E. DiCorleto
Cleveland Clinic Foundation
Lerner Research Institute
Cleveland, Ohio 44195

Abstract

The development of effective vascular therapies requires the understanding of all modes of vessel formation contributing to vasculogenesis, angiogenesis (here termed hemangiogenesis) and lymphangiogenesis. We show that lymphangiogenesis proceeds by blind-ended vessel sprouting via recruitment of isolated endothelial progenitor cells to the tips of growing vessels, whereas hemangiogenesis occurs by non-sprouting vessel expansion from the capillary network, during mid-development in the quail chorioallantoic membrane (CAM). Blood vessels expanded out of capillaries that displayed transient expression of alpha smooth muscle actin (α SMA), accompanied by mural recruitment of migratory progenitor cells expressing α SMA. Lymphatics and blood vessels were identified by confocal/fluorescence microscopy of vascular endothelial growth factor (VEGF) receptors VEGFR-1 and VEGFR-2, α SMA (expressed on CAM blood vessels but not on lymphatics), homeobox transcription factor Prox-1 (specific to CAM lymphatic endothelium), and the quail hematopoietic/vascular marker, QH-1. Expression of VEGFR-1 was highly restricted to blood vessels (primarily capillaries). VEGFR-2 was expressed intensely in isolated hematopoietic cells, lymphatic vessels and moderately in blood vessels. Prox-1 was absent from endothelial progenitor cells prior to lymphatic recruitment. Although vascular endothelial growth factor-165 (VEGF₁₆₅) is a key regulator of numerous cellular processes in hemangiogenesis and vasculogenesis, the role of VEGF₁₆₅ in lymphangiogenesis is less clear. Exogenous VEGF₁₆₅ increased blood vessel density without changing endogenous modes of vascular/lymphatic vessel formation or marker expression patterns. However,

VEGF₁₆₅ did increase the frequency of blood vascular anastomoses and strongly induced the anti-maturational dissociation of lymphatics from blood vessels, with frequent formation of homogeneous lymphatic networks.

Introduction

The understanding of all modes of vessel formation utilized in pathological vasculogenesis, hemangiogenesis and lymphangiogenesis is required for the development of effective vascular therapies. Developmental models are useful for initial understanding of these complex processes. Vasculogenesis is defined as the formation of a homogeneous, primary vascular network or plexus either within a developing embryo or organ, or during other *de novo* vascular growth such as wound-healing. The primary vascular network is usually remodeled by sprouting and/or non-sprouting modes of angiogenesis into a mature, nonhomogeneous branching tree (Risau, 1997; Gerhardt et al., 2003; Burri et al., 2004). In general, the term angiogenesis has been used to describe the growth of new blood vessels from pre-existing blood vessels. For increased clarity, we will refer to the angiogenic growth of blood vessels as hemangiogenesis (for example, see Cursiefen et al., 2004). Lymphangiogenesis is the growth of new lymphatic vessels and until recently, has been less studied with the tools of cellular and molecular biology (Oliver and Detmar, 2002; Scavelli et al., 2004). New results suggest that vasculogenesis includes the growth of either blood vessels or lymphatic vessels as homogeneous vascular endothelial networks (Wilting et al., 2004).

Blood vessels first form by vasculogenesis as homogeneous networks in the mouse embryonic allantois (Argraves et al., 2002), myocardial trabeculation and the yolk sac (Risau, 1997; Wang et al., 1999), the primordial quail vascular plexus (Vrancken Peters et al.; Wilting et al., 1997), the extraembryonic quail and chick chorioallantoic membrane (CAM, Caprioli et al., 2001), postnatal developing rat lung (Burri et al., 2004) and postnatal developing mouse retina (Benjamin et al., 1998). In the postnatal mouse retina, the homogeneous blood endothelial network is pruned into a mature branching vascular tree by cells expressing α SMA (Benjamin et al., 1998), and VEGF gradients expand the vascular network at its periphery by inducing new, sprouting angiogenic vessels guided by the filopodia of endothelial “tip cells” (Gerhardt et al., 2003). During hemangiogenesis in the avian CAM, the blood vascular tree grows and fills in by a quantifiable fractal growth process (Kirchner et al., 1996; Parsons-Wingerter et al., 1998; Parsons-Wingerter et al., 2000a).

The mammalian retina and avian CAM are useful for vascular morphogenesis studies because the vascular trees are highly two-dimensional (2D) and optically accessible within transparent tissue. In the bilaminar CAM, a homogeneous capillary network resides in the outer chorionic layer contiguous to the inner allantoic layer containing the blood vascular and lymphatic trees. Early homogenous vascular networks originating at E3-E4 in the quail CAM develop by E6 into branching blood vascular trees, and hemangiogenesis is complete by E9-E10. In embryonic vertebrates, lymphangiogenesis follows earlier development of the blood vascular system in a complex, rather intertwined fashion (Wigle and Oliver, 1999; Karkkainen et al., 2004; Wilting et al., 2004).

Vascular endothelial growth factor-A (VEGF-A) is a major regulator of blood vascular morphogenetic events that include endothelial cell proliferation, adhesion and migration, tubulogenesis, and vessel fusion and pruning (Ferrara et al., 2003; Nagy et al., 2003), but the effects of VEGF-A on lymphangiogenesis are not as well understood. VEGF₁₆₅ is generally the most hemangiogenic isoform of VEGF-A. In the quail CAM (Oh et al., 1997), exogenously applied isomers of VEGF-A, including VEGF₁₆₅, stimulated hemangiogenesis but not lymphangiogenesis. Conversely, exogenously applied VEGF-C, a VEGF family member that is recognized by VEGFR-3 and VEGFR-2 on lymphatic endothelium, stimulated lymphangiogenesis but not hemangiogenesis.

Quail hemangioblasts, which can differentiate into blood or lymphatic angioblasts, co-express VEGF receptor VEGFR-2 (also termed Flk-1, KDR and in quail, Quek-1) and the quail-specific hematopoietic marker QH-1 that is also expressed in blood and lymphatic endothelium. Blood endothelial cells in the quail CAM retain expression of QH-1 and VEGFR-2 (Caprioli et al., 2001). However, VEGFR-1 (also

termed Flt-1), which is widely co-expressed with VEGFR-2 in mammalian blood vessels, has not been identified in avian embryos until recently. VEGFR-1, strongly expressed in the trophoblast layer of mammalian placenta and currently viewed as a probable hemangiogenesis maturation factor, was identified in digests of the chicken embryo and CAM (Yamaguchi et al., 2002). Lymphatic endothelial cells in developing quail co-express QH-1, VEGFR-2, the lymphatic endothelial-specific VEGFR-3 (in quail, Quek-2) and a lymphatic endothelial-specific marker, the nuclear homeobox transcription factor Prox-1 (Papoutsis et al., 2001; Wilting et al., 2001; Scavelli et al., 2004; Wilting et al., 2004).

In this study, we investigated endogenous lymphangiogenesis and hemangiogenesis, and also exogenous stimulation by VEGF₁₆₅, in the rapidly growing quail CAM at E7-E8. By an interesting rescaling process during this 24-hour mid-developmental period, the CAM and its vascular tree double in size while continuing to increase vessel density (Parsons-Wingerter et al., 1998; Parsons-Wingerter et al., 2000a). We report here that vessel formation in the growing lymphatics and blood vessels occur by two simultaneous but contrasting modes of sprouting and non-sprouting vessel morphogenesis.

Methods and Materials

Culture, Assay and Mounting

Embryonic culture has been described previously (Parsons-Wingerter et al., 1998; Parsons-Wingerter et al., 2000a; Parsons-Wingerter et al., 2000b). Fertilized eggs of Japanese quail (*Coturnix coturnix japonica*, Boyd's Bird Co., Pullman, WA) were incubated at 37.6 ± 0.2 °C under ambient atmosphere, cracked at embryonic day three (E3, following incubation of eggs for 56 hours (h)) and cultured further at the same incubator conditions in petri dishes (cross-sectional area = 10 cm²). Quail egg culture and experimental methods were approved by the Animal Care Committee, University of Washington, and by the Chief Veterinarian Officer of NASA. At E7 (following incubation for an additional 96 h), 0.5 ml prewarmed PBS solution containing 100 µg/ml ovalbumin (Sigma, albumin chicken egg grade VII) and 0, 1.25 and 5 µg human recombinant VEGF₁₆₅ expressed in *E. coli* (G143AB, generous gift of Genentech) was applied dropwise to the surface of each CAM. Because the incubation solution is quickly absorbed into CAM tissue, the total amount of cytokine, rather than cytokine concentration, is the governing parameter and is therefore expressed as µg/CAM. CAM's responded positively to VEGF₁₆₅ from 1.25 to 5 µg/CAM; embryonic lethality increased at doses ≥ 10 µg/CAM. Results were consistent with those produced by human recombinant VEGF₁₆₅ (293-VE, R & D Systems) expressed in *SF 21* insect cells, except that 293-VE VEGF₁₆₅ appeared active at slightly lower concentrations. Following treatment with VEGF₁₆₅ and further incubation for 24 h, the embryos were fixed in 4 percent paraformaldehyde/PBS for fluorescence immunohistochemistry (IHC). Stimulation by VEGF₁₆₅ persisted in specimens treated for 48 h, but was not as strong as stimulation after 24 h.

Fluorescence Immunohistochemistry

Polyclonal, affinity-purified IgG antisera and monoclonal antibodies were applied to CAM specimens by conventional whole-mount fluorescence IHC (Drake and Little, 1995; Parsons-Wingerter et al., 2000b). Staining for nonspecific IgG controls in the IHC was low, and observations were made from numerous experiments and imagings. VEGFR-1 was identified primarily by goat sc-316g and confirmed by rabbit sc-316 (1:200 dilution, proprietary epitope from c-terminus of human VEGFR-1 with established cross-reactivity in human, mouse and rat, Santa Cruz Biotechnology). VEGFR-2 was labeled by RB-1526 (1:200 dilution, epitope from a 1326 to 1345, c-terminus of mouse Flk-1 precursor; Lab Vision). Lymphatics were identified by rabbit antiserum produced by immunization with the highly conserved C-terminus of Prox-1 that is cross-reactive in fish, chick, mouse, rat and human lymphatic endothelial cells (Protein A-purified, RDI-102PA30, Research Diagnostics). Smooth muscle cells were labeled by Cy3-conjugated anti- α SMA mouse monoclonal clone 1A4 (C6198, Sigma). The QH-1

monoclonal antibody (mouse ascites diluted 1:1000, Development Studies Hybridoma Bank, University of Iowa) specifically recognizes quail vasculature and hematopoietic precursor cells (Pardanaud et al., 1987; Coffin and Poole, 1991). Fluorescently labeled secondary antibodies conjugated to Alexa Fluor 488 and 568 were obtained from Molecular Probes, and secondary antibodies conjugated to Cy3 and Cy5, from Jackson ImmunoResearch. Nuclei were labeled with Hoechst 33342 (Molecular Probes MP H-3570).

After fixation with 4 percent paraformaldehyde/PBS at 4 °C for 48 h at E6-E7 and 24 h at E8-E9, specimens were blocked in 5 percent normal donkey serum (NDS)/1 percent Triton X-100/PBS, and incubated overnight at 4 °C with primary antibody in 0.2 percent NDS/PBS (except for RB-1526, incubated for 2 hours the following day), followed by incubation with secondary antibodies and mounting with 50 percent polyvinyl alcohol (PVA)/glycerol solution (Parsons-Wingerter et al., 1998), and 50 percent Vectashield™ (Vector Labs). Specimens were imaged with a Leica DM-RXE confocal microscope with TCS-SP2 scanner/Leica confocal software version 2.5 or a Leica DM-R fluorescence microscope with Micromax CCD-1300-V camera, Princeton Instruments and Image-Pro Plus Version 4.1.1.2 software. Volocity™ (sic) software (Improvision) was used for 3D reconstruction of confocal z-series images. Confocal images at 633x total magnification from specimens treated with VEGFR-2 antiserum RB-1526 were post-processed in Adobe Photoshop CS (version 8.0) to remove nonspecific background.

Results

Contrasting modes of vessel formation during endogenous lymphangiogenesis and hemangiogenesis, and the effects of exogenous VEGF₁₆₅ on these processes, were investigated in the quail CAM at E7-E8 with antibodies recognizing VEGFR-1, VEGFR-2, α SMA and Prox-1. The QH-1 monoclonal antibody was also used as a well-established marker of quail embryonic blood vasculature, hematopoietic precursor cells and lymphatic vessels according to QH-1 positivity and morphology described previously (Oh et al., 1997; Papoutsi et al., 2001). Lymphatics and blood vasculature were identified and distinguished from each other by morphology, and by the restricted localization of Prox-1 to lymphatics and α SMA to blood vessels. Smooth muscle cells are not present on lymphatics in the CAM (Papoutsi et al., 2001). Exogenous VEGF₁₆₅ was tested at concentrations that strongly stimulate increased vascular density (1.25 μ g/CAM) and increased vascular diameter (5 μ g/CAM). The fractal-based quantification of these concentration-dependent morphological changes induced by VEGF₁₆₅ will be described in detail elsewhere. Application of VEGF₁₆₅ stimulated hemangiogenesis and lymphangiogenesis, and induced several striking morphological changes described below. However, VEGF did not change lymphatic and vascular modes of vessel formation, and did not alter the expression patterns of lymphatic/vascular markers.

Staining for VEGFR-2 and QH-1 was highly colocalized, and expression of VEGFR-1 or VEGFR-2 was generally reciprocal (fig. 1). In control specimens at E7 and E8 (beginning and end of treatment by VEGF₁₆₅), VEGFR-2 and the QH-1 epitope were intensely expressed on round or elongate isolated cells, on lymphatic vessels, and at low or moderate levels on blood vessels and capillaries (fig. 1A and B). VEGFR-1 was abundantly expressed in a punctate fashion at the edges of capillaries (fig. 1D), was present at moderate to low levels on blood vessels (appearing more intense on smaller blood vessels), and was very weakly expressed or absent from lymphatic vessels and isolated cells (fig. 1C and D). The rather punctate nature of VEGFR-1 expression on capillaries, and the outlining of small blood vessels, was confirmed by two different polyclonal preparations (goat and rabbit IgG) recognizing the same human VEGFR-1 epitope compared to nonspecific IgG controls (results not shown). Expression of VEGFR-1 (fig. 1C to G) and VEGFR-2/QH-1 (figs. 1, 3, and 5) was not significantly altered by treatment with VEGF₁₆₅ at 1.25 and 5 μ g/CAM. Lymphatic vessels were further identified by localization of Prox-1 to lymphatic nuclei (fig. 2), as described previously by others (Papoutsi et al., 2001; Wilting et al., 2001).




Figure 1.—VEGFR-1 and VEGFR-2 are reciprocally expressed in lymphatics and blood vessels. (A, B) By IHC of control specimens at E8, the vascular/hematopoietic marker QH-1 (A) and VEGFR-2 (B) were essentially co-localized, although QH-1 stained smaller blood vessels and the capillaries with somewhat greater intensity. Expression of QH-1 and VEGFR-2 was most intense in single isolated cells (hollow arrow, A) and in lymphatic vessels (large lymphatic plexus surrounding large blood vessel, arrowhead; smaller lymphatic vessel adjacent to smaller blood vessels, arrow), with moderate to low expression on blood vessels (hollow arrowhead) and capillaries (red arrowhead, see also C). The lymphatics were further distinguished from the blood vasculature by their distinctive morphology and by the lymphatic-specific marker Prox-1 (see fig. 2). VEGFR-1 expression (red, C to G) was generally reciprocal to VEGFR-2 (B) and QH-1 (A and D). VEGFR-1 was localized primarily to the capillary lumen in a punctate fashion (C to G), was present in moderate abundance on some smaller blood vessels (arrowhead, C), and was essentially absent from lymphatic vessels, larger blood vessels and most isolated cells. Relative to untreated controls (D and E), VEGFR-1 expression was not altered significantly in response to application of VEGF₁₆₅ at 1.25 μg/CAM (F) and 5 μg/CAM (G). A to G: All confocal images.




Figure 2.—Expression of Prox-1 in lymphatic vessels.
 (A) Expression of the lymphatic endothelial-specific marker Prox-1, a homeobox transcription factor localized to the nucleus, was restricted to lymphatic endothelium. Prox-1 further confirmed identification of the lymphatic vessels enclosing the blood vessels.

The diameters of lymphatic vessels, and perhaps lymphatic density, increased in response to VEGF₁₆₅ at 1.25 and 5 μg/CAM (fig. 3), which is consistent with the established effect of VEGF₁₆₅ as a vascular permeability factor resulting in increased serum leakage from blood vessels. Notably, the lymphatics were highly detached from medium-sized and smaller blood vessels, relative to control specimens (fig. 3A, and C to E). The frequent network-like organization of lymphatics resembled early lymphatic morphology as a homogeneous vascular network observed at E5-E6 in untreated specimens (fig. 3B), prior to the later, more mature, close association of lymphatic vessels with blood vessels. Treatment with VEGF₁₆₅ at 1.25 μg/CAM resulted in increased blood vascular density accompanied by the increased frequency of blood vascular anastomoses (fig. 4A, C, and D). These anastomoses were relatively frequent in normal specimens at E6-E7 and became infrequent by E8-E10. Increases in the diameter of blood vessels were observed most frequently in specimens treated with 5 μg VEGF₁₆₅/CAM (results not shown, because increases in vessel diameter are dependent on branching location in the vascular tree; see figs. 1 and 3).




Figure 3.—VEGF₁₆₅ increases the diameter and density of lymphatic vessels, and induces lymphatic dissociation from blood vessels. (A and C to E) By IHC of VEGFR-2 (green) and QH-1 (red) relative to control specimens (A), lymphatic vessels (arrowheads) enlarged and dissociated from blood vessels (arrows) in response to the application of VEGF₁₆₅ at 1.25 $\mu\text{g}/\text{CAM}$ (C) and 5 $\mu\text{g}/\text{CAM}$ (D). (E) The lymphatics frequently reassociated as a network (hollow arrowhead) when treated with 1.25 or 5 μg VEGF/CAM, which is a regression of lymphatic morphology to homogeneous vascular networks observed in the normal CAM at E5-E6 (B, visualized by QH-1). (A and C to E) Note large numbers of single, isolated cells co-expressing VEGFR-2 and QH-1. A and C to E: Confocal images. B: Fluorescence image.




Figure 4.—VEGF₁₆₅ increases blood vessel density during hemangiogenesis by vascular expansion from the capillary network. (A and C) In control specimens expressing αSMA at E8, post-capillary venules (PCV, arrowheads) and an arteriole (arrow) emerge from the capillary network, displaying larger round gaps arranged in a parallel fashion, and brighter staining, compared to smaller, less intense, non-parallel round gaps (holes) of the intercapillary spaces. Staining of the round capillary gaps is clear but transitory, and is no longer present in mature capillaries at E9-E10 or on immunological control specimens untreated with antibody recognizing αSMA (results not shown). (B) Fine processes (arrowhead) of αSMA, an enlarged detail from PCV (A, arrowhead), span the distance between two neighboring gaps of the PCV emerging from the capillary bed. (C) Arrowheads indicate post-capillary venules (PCVs), and the arrow points to an arteriole, according to the more discontinuous pericyte and smooth muscle coverage of the PCVs, as well as venular and arteriolar connections to larger parent veins and arteries (not shown). (D) Following application of VEGF₁₆₅ at 1.25 μg/CAM, blood vessels displayed more frequent, abnormal anastomoses (arrowhead) relative to controls (A and C). (E) At E6 in untreated controls, many single cells expressing αSMA are merging with blood vessels (arrowheads). Compared to decreased frequencies in untreated controls at E8 (A, C, and F), αSMA-positive cells merge with blood vessels at increased frequencies in control specimens at E6 (E) and VEGF-treated specimens at E8 (G) although these frequencies vary throughout CAMs of all specimens. A to D and G: Fluorescence images. E and F: Confocal images.




Figure 5.—VEGF₁₆₅ stimulates lymphangiogenesis, but not hemangiogenesis, by progenitor cell recruitment to the tips of sprouting vessels. By IHC of control specimens at E7 expressing (A) α SMA and (B) QH-1 (as co-localized with VEGFR-2), small blood vessels (arrowheads) emerge directly from the capillary network. This field (A and B) is a small region (C, arrowhead) adjacent to the larger blood vessel enclosed by a lymphatic network containing numerous blind-ended lymphatic sprouts. (D) At higher magnification, lymphatic sprouts led by tip cells with filopodia (arrowhead) are growing by recruitment of isolated endothelial cells to the lymphatics. (E and F) Filopodial processes of lymphatic tip cells (arrowhead) are clearly shown. The lymphatic tip cells are details from a well-developed lymphatic network enclosing a large blood vessel, as shown at lower magnification in C and D. (G and H) In specimens treated with VEGF₁₆₅ at 1.25 μ g/CAM, the small, anastomotic blood vessels emerge directly from the capillary network (arrowhead). (I) In the thickened lymphatic network enclosing a large blood vessel from a more mature control specimen at E9, lymphatic sprouts with tip cells displaying filopodia are still present.

Single cells expressing α SMA and displaying a pericyte/smooth muscle migratory phenotype were prominent in control and VEGF-treated samples (figs. 3 and 4). These cells were often imaged as merging with blood vessels (fig. 4E to G). The frequency of α SMA-positive cells was variable throughout a specimen. Treatment with VEGF₁₆₅ appeared to increase the numbers of isolated cells expressing α SMA (figs. 3 and 4). In untreated specimens, isolated cells expressing either VEGFR-2/QH-1 or α SMA were very numerous at E6-E7, declined in number by E9, and were infrequent at E10. Capillaries consistently expressed α SMA at low levels as cortical staining around the intercapillary gaps (fig. 4). This pattern of α SMA expression, the size of the circular intercapillary gaps, and the linear realignment of the gaps into a parallel arrangement increased significantly in capillary regions where either pre-existing arterioles and venules merged into the capillary network or new arterioles and venules were beginning to form. This transient capillary expression of α SMA, which appears to support the process of blood vessel expansion out of the capillaries, stopped by E9-E10.

Non-Sprouting Hemangiogenesis by Vessel Expansion From the Capillary Network

At E7-E8, endogenous and VEGF-stimulated hemangiogenesis in the CAM resulted by a non-sprouting vascular expansion (i.e., emergence) of arterioles and post-capillary venules from the capillary network (figs. 4A to C; 5A and B, and G to H). No vascular tip cell displaying extended filopodia or positive expression of VEGFR-2/QH-1 was observed on blood vessels in control or VEGF-treated specimens during this relatively mature phase of hemangiogenesis in the CAM. Discontinuous walls of smooth muscle cells appeared to emerge from the capillary network in part by stronger expression of α SMA on the side of the blood vessel proximal to capillaries. These changes in the expression of α SMA colocalized with the expression patterns of QH-1 in endothelial cells that continued in part to resemble the plexus-like morphology of capillaries (fig. 5A and B). New, small blood vessels subsequently were invested with smooth muscle coverage on the distal side of growing vessels by extending and connecting the α SMA-positive processes, and then broadening these processes.

Lymphangiogenic Sprouting via Filopodial Guidance of Tip Cells

At E7-E8, lymphangiogenesis in both control and VEGF-treated specimens (fig. 3) proceeded by the sprouting of lymphatic vessels guided by the filopodia of tip cells, as identified by positive expression of Prox-1, VEGFR-2 and QH-1 (figs. 1, 3, and 5). The tip cells appeared to be recruited to the blind-ended vessel sprouts from a large population of isolated, polarized endothelial progenitor cells located on: (1) large, well-developed lymphatic networks tightly enclosing larger blood vessels, (2) the ends of smaller lymphatics loosely associated with smaller blood vessels, and (3) isolated lymphatics or lymphatic networks either at the periphery of the CAM or throughout the CAM following stimulation by VEGF₁₆₅. In control specimens, lymphatic tip cells displaying filopodia were very frequently visible at E6-E7 (fig. 3B) and decreasing in number by E8. Tip cells were still present at E9, although overall lymphatic architecture was smoother, thicker and accompanied by fewer numbers of VEGFR-2+ isolated cells (fig. 5I). Lymphatic tip cells thus appear to play a critical role in the development, and perhaps maintenance and function, of well-connected CAM lymphatic networks. Although clearly recruited from isolated endothelial progenitor cells, it is not known whether tip cells were also produced by cell division within blind-ended lymphatic sprouts. We saw little evidence for recruitment of isolated endothelial precursors to the growing trunks of lymphatic vessels, but do not rule this out as a possible additional contribution to the overall lymphangiogenic process.

Summary

During endogenous lymphangiogenesis, isolated endothelial progenitor cells were recruited to the tips of sprouting, blind-ended lymphatic vessels. During endogenous hemangiogenesis, new blood vessels

connected to the rapidly expanding vascular tree grew by non-sprouting vessel expansion out of the pre-existing, homogeneous capillary network. Specimens treated exogenously with human VEGF₁₆₅ displayed increased vascular density, more frequent vascular anastomoses, the anti-maturational, regressive dissociation of lymphatic vessels from blood vessels, and the frequent reassociation of lymphatics into a homogenous vascular network. However, no major differences in the sprouting and non-sprouting modes of lymphatic and blood vessel formation were found between control and VEGF-treated specimens.

Discussion

The major finding of our investigative study of simultaneous, coordinate hemangiogenesis and lymphangiogenesis in the quail CAM at E7-E8 is that vessel formation occurred by the two contrasting morphogenetic modes of non-sprouting vessel expansion versus vessel sprouting, respectively (fig. 6). Exogenous application of VEGF₁₆₅ accelerated, but did not change, endogenous lymphatic and vascular modes of vessel formation. However, VEGF₁₆₅ did induce frequent anastomoses in smaller blood vessels and the anti-maturational dissociation of lymphatics from their close, highly organized association with blood vessels, as well as frequent lymphatic reassociation into more homogeneous networks. Exogenous VEGF₁₆₅ did not alter the expression patterns of various vascular and lymphatic markers.

During hemangiogenesis (fig. 6A and B), new blood vessels emerged from out of the chorionic capillaries to enlarge the rapidly growing allantoic vascular tree. As identified by QH-1, VEGFR-1, VEGFR-2 and α SMA, the blood vessels did not grow by vascular sprouting. Instead, a growing vessel remained connected to the capillary bed at one end and to a larger parent artery or vein at the other. The parent arteries and veins vary considerably in size because the most frequent branching event in the growing CAM (as in the heart and lung of the adult dog and pig), is the offshoot of a small child or daughter vessel from a larger parent vessel, not the dichotomous branching of a parent vessel into two equivalent “child” or daughter vessels (Gan et al., 1993; Kassab et al., 1993; Kassab et al., 1994; Parsons-Wingenter et al., 2000a; Parsons-Wingenter et al., 2000b). Cortical expression of α SMA occurred transiently within capillaries, presumably to facilitate the process of vessel expansion. Capillary expression of α SMA intensified in the regions that were either merging or transforming into new vessels. Bundled cables of α SMA were extended around the growing new vessels; isolated, α SMA-positive cells of polarized, migratory phenotype were also recruited to the walls of smooth muscle or pericyte cells discontinuously covering new blood vessels.

The non-sprouting expansion of the blood vessels reported by us shares important characteristics with the non-sprouting mode of hemangiogenesis termed intussusception, described for the hemangiogenic transformation of homogeneous capillary networks formed in developing rat lung and the chicken CAM by vascular casting and electron microscopy (Patan et al., 1996; Burri et al., 2004). For example, according to both non-sprouting modes of hemangiogenesis, parallel holes in the capillary plexus define emerging blood vessels. These intercapillary holes, described by Burri and co-workers as the sites of non-vascular tissue pillars, become increasingly prominent as new vessels grow and separate from the capillary bed. In the hemangiogenic vessel expansion observed by us, new, emergent vessels often appear as incomplete, transitional tubes, and not as the closed tubes described by intussusceptive hemangiogenesis (see especially fig. 5A and B). We recognize that this could be due to our incomplete labeling of truly extant tubular blood vessels by the vascular markers QH-1 and VEGFR-2. Coverage of post-capillary venules by pericytes and smooth muscle cells is generally discontinuous. On the other hand, the anastomotic blood vessels stimulated by our treatment with VEGF₁₆₅ appear as closed tubes, and strongly resemble the remodeling blood vessels created by enlarging tissue pillars during intussusception (see fig. 5G and H).




Figure 6.—Model of hemangiogenic expansion and lymphatic sprouting as stimulated by VEGF₁₆₅ in the CAM. (A) **Hemangiogenic Expansion:** At E6-E8, the capillary network and vascular tree are actively developing in response to stimulation by VEGF₁₆₅ and ongoing hemangiogenesis. Migrating cells positive for α SMA are frequently recruited to growing blood vessels, and the highly plastic capillaries are temporarily positive for α SMA. Small new arterioles and post-capillary venules (PCV) arise out of the capillary network. New, small regions of these emerging vessels display a larger gap size in the smooth muscle layer relative to more mature regions that are proximal to larger blood vessels. (B) Round gaps of smooth muscle become less prominent as blood vessels enlarge and mature, and isolated cells positive for α SMA or VEGFR-2 disappear. It is not clear to us whether the precursor cells expressing VEGFR-2 are recruited to growing blood vessels. (C) **Lymphatic Sprouting:** The growing lymphatic network, which is relatively homogeneous at E6, differentiates by attaching and growing as prominent networks around large blood vessels, and as loosely associated vessels around smaller blood vessels. The lymphatics, which are strongly positive for VEGFR-2 and negative for α SMA, recruit VEGFR-2 expressing lymphatic progenitor cells to the tips of blind-ended sprouts on vessels and in networks. (D) As a detail of (C), tip cells display numerous, prominent filopodia, most of which later fuse with the growing lymphatic vessel. Newly recruited tip cells continue to express VEGFR-2 and begin to express Prox-1.

During lymphangiogenesis (fig. 6C and D), isolated endothelial precursor cells intensely co-expressing VEGFR-2 and QH-1 were recruited to the tips of blind-ended lymphatic sprouts. Upon recruitment, the tip cells quickly displayed numerous, long, filopodial processes and positively expressed the lymphatic endothelial marker Prox-1, in addition to continuing expression of VEGFR-2 and QH-1. Tip cells of different lymphatic vessels frequently contacted each other by their filopodia, prior to subsequent joining of the lymphatic vessels into a growing lymphatic network tightly enclosing a large blood vessel, or a more extensive lymphatic branching tree around a smaller blood vessel.

As revealed by fluorescence IHC, expression of the receptors VEGFR-1 and VEGFR-2 was highly reciprocal. Expression of VEGFR-2 in the quail CAM was intense on isolated endothelial progenitor cells, strong on lymphatic endothelial cells and the filopodial processes of the lymphatic tip cells, and weak on blood vessels and capillaries. Strong co-expression of VEGFR-2 and lymphatic-specific VEGFR-3 was reported for developing lymphatics of the quail and chicken CAM (Oh et al., 1997). The expression of VEGFR-2 on lymphatics has not been widely reported. However, molecular profiling demonstrated that lymphatic endothelial cells can express VEGFR-2 (Podgrabinska et al., 2002). The expression of VEGFR-1 was prominent in the capillaries and a few isolated cells, and appeared to weakly line the surface of smaller blood vessels. Perhaps due to its low abundance relative to VEGFR-2, VEGFR-1 has not been identified previously in the blood vessels of the avian CAM. The pronounced punctate expression of VEGFR-1, perhaps related to the regulation of growth cessation in CAM capillaries, is intriguing. However, it is not clear from our histological study how VEGFR-1 expression in the CAM is consistent with the maturational role proposed for VEGFR-1 in the formation of blood vessels, in which VEGFR-1 helps to halt vascular growth (Eriksson and Alitalo, 2002; Lutun et al., 2002). Embryonic mice deficient in VEGFR-1 die prenatally with excessive numbers of endothelial cells in the blood vasculature (Fong et al., 1999). In CAM capillaries, VEGFR-1 may also assist in regulation of hematopoietic cell recruitment and mobilization (Hattori et al., 2002).

Spatial gradients of VEGF concentration were reported to guide the filopodia of endothelial tip cells expressing VEGFR-2 during sprouting hemangiogenesis in the postnatal mouse retina (Gerhardt et al., 2003). Precise concentration gradients of VEGF-A support chemotactic cell migration and are required for correct blood vascular development *in vivo* (Carmeliet et al., 1996; Ferrara et al., 1996; Yoshida et al., 1996; Ozawa et al., 2004). In addition to the well-established evidence for induction of lymphangiogenesis by VEGF-C (for example, Jeltsch et al., 1997), there is some evidence that VEGF-A can also induce lymphatic tube formation (Nagy et al., 2002; Cursiefen et al., 2004). Recognized by VEGFR-2 and VEGFR-3 but not VEGFR-1, VEGF-C is expressed throughout the allantoic bud and during later CAM development, and is restricted primarily to the tunica media of the mural wall in larger blood vessels and the allantoic epithelium (Wilting et al., 2001). The localized expression of VEGF-C on larger blood vessels could account for the close attachment of large lymphatic networks to these vessels observed by us and others. The VEGF₁₆₅-induced dissociation of the lymphatics from the blood vessels reported here, and their frequent reassociation into homogeneous lymphatic networks, may be due to disruption of VEGF-C chemotactic gradients, and/or concentration-dependent signaling to its receptor VEGFR-2.

We have described in this report a sprouting mode of lymphangiogenesis simultaneous to a non-sprouting mode of hemangiogenesis in the quail CAM during mid-development at E7-E8. As summarized in the Introduction, sprouting and non-sprouting modes of VEGF-regulated hemangiogenesis following primordial vasculogenesis have been reported previously, particularly in developing mouse, quail and chicken. The complex regulation of hemangiogenesis and lymphangiogenesis by the VEGF family is tissue and program-specific (for example, Byzova et al., 2002), and much has been learned about the cellular and molecular biology of the VEGFs. Fundamental, useful principles of VEGF-regulated blood and lymphatic vessel morphogenesis are also becoming more clear.

References

- Argraves WS, Larue AC, Fleming PA, Drake CJ. 2002. VEGF signaling is required for the assembly but not the maintenance of embryonic blood vessels. *Dev. Dyn.* 225:298–304.
- Benjamin LE, Hemo I, Keshet E. 1998. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. *Development* 125:1591–1598.
- Burri PH, Hlushchuk R, Djonov V. 2004. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. *Dev. Dyn.* 231:474–488.
- Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, Carnevale KA, Siemionow M, Deitcher SR, DiCorleto PE. 2002. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. *Blood* 99:4434–4442.
- Caprioli A, Minko K, Drevon C, Eichmann A, Dieterlen-Lievre F, Jaffredo T. 2001. Hemangioblast commitment in the avian allantois: cellular and molecular aspects. *Dev. Biol.* 238:64–78.
- Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Kendraprasad H, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* 380:435–439.
- Coffin JD, Poole TJ. 1991. Endothelial Cell Origin and Migration in Embryonic Heart and Cranial Blood Vessel Development. *Anat. Rec.* 231:383–395.
- Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW. 2004. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. *J Clin Invest* 113:1040–1050.
- Drake CJ, Little CD. 1995. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. *Proc. Natl. Acad. Sci. USA* 92:7657–7661.
- Eriksson U, Alitalo K. 2002. VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. *Nat. Med.* 8:775–777.
- Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature* 380:439–442.
- Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. *Nat. Med.* 9:669–676.
- Fong GH, Zhang L, Bryce DM, Peng J. 1999. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in *flt-1* knock-out mice. *Development* 126:3015–3025.
- Gan RZ, Tian Y, Yen RT, Kassab GS. 1993. Morphometry of the dog pulmonary venous tree. *J. Appl. Physiol.* 75:432–440.
- Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. 2003. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J. Cell Biol.* 161:1163–1177.
- Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L, Hendrikx J, Hackett NR, G. CR, Moore MA, Werb Z, Lyden D, Rafii S. 2002. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) cells from bone-marrow microenvironment. *Nat. Med.* 8:841–849.
- Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K. 1997. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. *Science* 276:1423–1425.
- Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. 2004. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. *Nat Immunol* 5:74–80.
- Kassab GS, Lin DH, Fung YC. 1994. Morphometry of pig coronary venous system. *Am. J. Physiol.* 267:H2100–2113.

- Kassab GS, Rider CA, Tang NJ, Fung YC. 1993. Morphometry of pig coronary arterial trees. *Am. J. Physiol.* 265:H350–365.
- Kirchner LM, Schmidt SP, Gruber BS. 1996. Quantitation of angiogenesis in the chick chorioallantoic membrane model using fractal analysis. *Microvasc. Res.* 51:2–14.
- Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compennolle V, Daci E, Bohlen P, Dewerchin M, Herbert J-M, Fava R, Matthys P, Carmeliet G, Collen D, F. DH, Hicklin DJ, Carmeliet P. 2002. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. *Nat. Med.* 8:831–840.
- Nagy JA, Dvorak AM, Dvorak HF. 2003. VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. *Trends Cardiovasc. Med.* 13:169–175.
- Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF. 2002. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. *J Exp Med* 196:1497–1506.
- Oh SJ, Jeltsch MM, Birkenhager R, McCarthy JE, Weich HA, Christ B, Alitalo K, Wilting J. 1997. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. *Dev. Biol.* 188:96–109.
- Oliver G, Detmar M. 2002. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. *Genes Dev* 16:773–783.
- Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, Kraft PE, McDonald DM, Blau HM. 2004. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. *J. Clin. Invest.* 113:516–527.
- Papoutsi M, Tomarev SI, Eichmann A, Prols F, Christ B, Wilting J. 2001. Endogenous origin of the lymphatics in the avian chorioallantoic membrane. *Dev. Dyn.* 222:238–251.
- Pardanaud L, Altman C, Kitos P, Dieterlen-Lievre F, Buck CA. 1987. Vasculogenesis in the early quail blastodisc as studied with a monoclonal antibody recognizing endothelial cells. *Development* 100:339–349.
- Parsons-Wingerter P, Elliott KE, Clark JI, Farr AG. 2000b. Fibroblast growth factor-2 selectively stimulates angiogenesis of small vessels in arterial tree. *Arterioscler. Thromb. Vasc. Biol.* 20:1250–1256.
- Parsons-Wingerter P, Elliott KE, Farr AG, Radhakrishnan K, Clark JI, Sage EH. 2000a. Generational analysis reveals that TGF-beta1 inhibits the rate of angiogenesis in vivo by selective decrease in the number of new vessels. *Microvasc. Res.* 59:221–232.
- Parsons-Wingerter P, Lwai B, Yang MC, Elliott KE, Milaninia A, Redlitz A, Clark JI, Sage EH. 1998. A novel assay of angiogenesis in the quail chorioallantoic membrane: stimulation by bFGF and inhibition by angiostatin according to fractal dimension and grid intersection. *Microvasc. Res.* 55:201–214.
- Patan S, Haenni B, Burri PH. 1996. Implementation of intussusceptive microvascular growth in the chicken chorioallantoic membrane. *Microvasc. Res.* 51:80–98.
- Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper MS, Skobe M. 2002. Molecular characterization of lymphatic endothelial cells. *Proc Natl Acad Sci U S A* 99:16069–16074.
- Risau W. 1997. Mechanisms of angiogenesis. *Nature* 386:671–674.
- Scavelli C, Weber E, Agliano M, Cirulli T, Nico B, Vacca A, Ribatti D. 2004. Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. *J Anat* 204:433–449.
- Vrancken Peters MP, Gittenberger-de Groot AC, Mentink MM, Hungerford JE, Little CD, Poelmann RE. The development of the coronary vessels and their differentiation into arteries and veins in the embryonic heart.
- Wang F, Lu W, McKeehan K, Mohamedali K, Gabriel JL, Kan M, McKeehan WL. 1999. Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. *Biochem.* 38:160–171.

- Wigle JT, Oliver G. 1999. Prox1 function is required for the development of the murine lymphatic system. *Cell* 98:769–778.
- Wilting J, Eichmann A, Christ B. 1997. Expression of the avian VEGF receptor homologues Quek1 and Quek2 in blood-vascular and lymphatic endothelial and non-endothelial cells during quail embryonic development. *Cell Tissue Res.* 288:207–223.
- Wilting J, Papoutsi M, Becker J. 2004. The lymphatic vascular system: secondary or primary? *Lymphology* 37:98–106.
- Wilting J, Papoutsi M, Othman-Hassan K, Rodriguez-Niedenfuhr M, Prols F, Tomarev SI, Eichmann A. 2001. Development of the avian lymphatic system. *Microsc. Res. Tech.* 55:81–91.
- Yamaguchi S, Iwata K, Shibuya M. 2002. Soluble Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. *Biochem. Biophys. Res. Comm.* 291.
- Yoshida A, Anand-Apte B, Zetter BR. 1996. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. *Growth Factors* 13:57–64.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 2005	3. REPORT TYPE AND DATES COVERED Technical Memorandum	
4. TITLE AND SUBTITLE By Different Cellular Mechanisms, Lymphatic Vessels Sprout by Endothelial Cell Recruitment Whereas Blood Vessels Grow by Vascular Expansion			5. FUNDING NUMBERS Cost Center 22IRD0009	
6. AUTHOR(S) Patricia Parsons-Wingerter, Terri L. McKay, Dmitry Leontiev, Terence K. Condrich, and Paul E. DiCorleto				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) National Aeronautics and Space Administration John H. Glenn Research Center at Lewis Field Cleveland, Ohio 44135-3191			8. PERFORMING ORGANIZATION REPORT NUMBER E-15183	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) National Aeronautics and Space Administration Washington, DC 20546-0001			10. SPONSORING/MONITORING AGENCY REPORT NUMBER NASA TM-2005-213824	
11. SUPPLEMENTARY NOTES Patricia A. Parsons-Wingerter, NASA Glenn Research Center (supporting the Cleveland Clinic Foundation, Lerner Research Institute, Department of Cell Biology, Cleveland, Ohio 44195); Terry L. McKay, National Center for Space Exploration Research, 21000 Brookpark Road, Cleveland, Ohio 44135; Dmitry Leontiev, the Cleveland Clinic Foundation, Lerner Research Institute, Imaging Core Facility, Cleveland, Ohio 44195 (currently at Case Western Reserve University, Epidemiology and Biostatistics, Cleveland, Ohio 44106); Terry Condrich, RS Information Systems, Inc., 21000 Brookpark Road, Cleveland, Ohio 44135; and Paul E. DiCorleto, the Cleveland Clinic Foundation, Lerner Research Institute, Department of Cell Biology, Cleveland, Ohio 44195. Responsible person, Patricia A. Parsons-Wingerter, organization code RUB, 216-433-8796.				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Unclassified - Unlimited Subject Category: 51 Available electronically at http://gltrs.grc.nasa.gov This publication is available from the NASA Center for AeroSpace Information, 301-621-0390.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) The development of effective vascular therapies requires the understanding of all modes of vessel formation contributing to vasculogenesis, angiogenesis (here termed hemangiogenesis) and lymphangiogenesis. We show that lymphangiogenesis proceeds by blind-ended vessel sprouting via recruitment of isolated endothelial progenitor cells to the tips of growing vessels, whereas hemangiogenesis occurs by non-sprouting vessel expansion from the capillary network, during mid-development in the quail chorioallantoic membrane (CAM). Blood vessels expanded out of capillaries that displayed transient expression of alpha smooth muscle actin (α SMA), accompanied by mural recruitment of migratory progenitor cells expressing α SMA. Lymphatics and blood vessels were identified by confocal/fluorescence microscopy of VEGF receptors VEGFR-1 and VEGFR-2, α SMA (expressed on CAM blood vessels but not on lymphatics), homeobox transcription factor Prox-1 (specific to CAM lymphatic endothelium), and the quail hematopoietic/vascular marker, QH-1. Expression of VEGFR-1 was highly restricted to blood vessels (primarily capillaries). VEGFR-2 was expressed intensely in isolated hematopoietic cells, lymphatic vessels and moderately in blood vessels. Prox-1 was absent from endothelial progenitor cells prior to lymphatic recruitment. Although vascular endothelial growth factor-165 (VEGF ₁₆₅) is a key regulator of numerous cellular processes in hemangiogenesis and vasculogenesis, the role of VEGF ₁₆₅ in lymphangiogenesis is less clear. Exogenous VEGF ₁₆₅ increased blood vessel density without changing endogenous modes of vascular/lymphatic vessel formation or marker expression patterns. However, VEGF ₁₆₅ did increase the frequency of blood vascular anastomoses and strongly induced the anti-maturational dissociation of lymphatics from blood vessels, with frequent formation of homogeneous lymphatic networks.				
14. SUBJECT TERMS Cardiovascular system; Lymphatic system; Fractals; Lymphangiogenesis; Hemangiogenesis; Sprouting; VEGF; Vascular; Chorioallantoic membrane; CAM; Quail; Avian			15. NUMBER OF PAGES 22	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT	

